Strain identifier

BacDive ID: 14449

Type strain: No

Species: Staphylococcus aureus

Strain Designation: Wichita

Culture col. no.: CCUG 15915, DSM 2569, ATCC 29213, WDCM 00131, JCM 2874, CCM 4223, CECT 794, CIP 103429, IFO 15035, LMG 10147, NBIMCC 3999, NBRC 15035, NCTC 12973

Strain history: R. Sakazaki 85047 <-- ATCC 29213 <-- Micro-Media Systems, Inc. <-- E. H. Gerlach strain Wichita.

NCBI tax ID(s): 1280 (species)

« Browse strain by BacDive ID »

expand / minimize allblue arrow down

Exclude non-curated data/information

Staphylococcus aureus Wichita is a mesophilic human pathogen that was isolated from wound.

  1. human pathogen
  2. mesophilic
  3. 16S sequence
  4. Bacteria
  5. genome sequence
  • Availability in culture collections External linksarrow_down
  • [Ref.: #1123] Culture collection no. CCUG 15915, DSM 2569, ATCC 29213, WDCM 00131, JCM 2874, CCM 4223, CECT 794, CIP 103429, IFO 15035, LMG 10147, NBIMCC 3999, NBRC 15035, NCTC 12973
    [Ref.: #20218] Associated Passport(s) in StrainInfo 21815, 21814, 866239
    Literature: Only first 10 entries are displayed. Click here to see all.Click here to see only first 10 entries.
    Topicarrow to sort Titlearrow to sort Authorsarrow to sort Journalarrow to sort DOIarrow to sort Yeararrow to sort
    Metabolism Quinolone accumulation in Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus. McCaffrey C, Bertasso A, Pace J, Georgopapadakou NH Antimicrob Agents Chemother 10.1128/AAC.36.8.1601 1992 *
    Pathogenicity Improved method for electroporation of Staphylococcus aureus. Schenk S, Laddaga RA FEMS Microbiol Lett 10.1016/0378-1097(92)90596-g 1992 *
    Pathogenicity Antimicrobial activity of RU29246 (HR916 metabolite) compared with four other oral beta-lactams tested against more than 5000 clinical isolates. Murray PR, Allen SD, Erwin ME, Gerlach EH, Jones RN, Koontz FP, Pfaller MA, Washington JA 2nd Eur J Clin Microbiol Infect Dis 10.1007/BF01972510 1991 *
    Pathogenicity In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci. Fass RJ Antimicrob Agents Chemother 10.1128/AAC.35.3.553 1991 *
    Pathogenicity Interpretive criteria for disk diffusion susceptibility testing of sparfloxacin. Kayser FH, Wust J Eur J Clin Microbiol Infect Dis 10.1007/BF01964449 1991 *
    Pathogenicity In-vitro postantibiotic effects of miocamycin and erythromycin on gram-positive cocci. Varotto F, Garlaschi ML, Garlaschi MC, Falchi M, Scaglione F, Cattaneo G, De Luca M, Fraschini F J Chemother 10.1080/1120009x.1990.11739043 1990 *
    Pathogenicity Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria. Fuchs PC, Jones RN, Barry AL, Gavan TL J Clin Microbiol 10.1128/jcm.27.1.49-52.1989 1989 *
    Pathogenicity Quality control limits for microdilution susceptibility tests with norfloxacin. Barry AL, Gavan TL, Ayers LW, Fuchs PC, Gerlach EH, Thornsberry C J Clin Microbiol 10.1128/jcm.25.1.165-166.1987 1987 *
    Pathogenicity Disk diffusion susceptibility testing and broth microdilution quality control guidelines for BMY-28100, a new orally administered cephalosporin. Jones RN, Barry AL J Clin Microbiol 10.1128/jcm.25.11.2211-2213.1987 1987 *
    Pathogenicity In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101. Barry AL, Aldridge KE, Allen SD, Fuchs PC, Gerlach EH, Jones RN, Pfaller MA Eur J Clin Microbiol Infect Dis 10.1007/BF01975053 1988 *